




RealRate

PHARMACEUTICAL 2019

Sarepta Therapeutics Inc
Rank 163 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Sarepta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 39% points. The greatest weakness of Sarepta Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 280%, being 31% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	1,426,183
Cost of Goods Sold	0
Intangible Assets	11,574
Liabilities, Current	173,690
Liabilities, Non-Current	15,555
Other Assets	107,294
Other Compr. Net Income	280
Other Expenses	34,366
Other Liabilities	420,554
Other Net Income	-18,982
Other Revenues	301,034
Property and Equipment	97,024
Research and Development	401,843
Selling, General and Administrative Expense	207,761

Output Variable	Value in 1000 USD
Assets	1,642,075
Liabilities	609,799
Expenses	643,970
Revenues	301,034
Stockholders Equity	1,032,276
Net Income	-361,918
Comprehensive Net Income	-361,778
BaseVar	1,608,070
ECR before Limited Liability	168%
Economic Capital Ratio	280%